Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Systemic Sclerosis (Scleroderma) Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Systemic Sclerosis (Scleroderma) Overview | 12 | 1 |
| Pipeline Products for Systemic Sclerosis (Scleroderma) Comparative Analysis | 13 | 1 |
| Systemic Sclerosis (Scleroderma) Therapeutics under Development by Companies | 14 | 2 |
| Systemic Sclerosis (Scleroderma) Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Systemic Sclerosis (Scleroderma) Pipeline Products Glance | 17 | 4 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Unknown Stage Products | 20 | 1 |
| Systemic Sclerosis (Scleroderma) Products under Development by Companies | 21 | 2 |
| Systemic Sclerosis (Scleroderma) Products under Investigation by Universities/Institutes | 23 | 1 |
| Systemic Sclerosis (Scleroderma) Companies Involved in Therapeutics Development | 24 | 31 |
| Allergan Plc | 24 | 1 |
| Angion Biomedica Corp. | 25 | 1 |
| Antitope Limited | 26 | 1 |
| Bayer AG | 27 | 1 |
| BioLineRx, Ltd. | 28 | 1 |
| BiOrion Technologies B.V. | 29 | 1 |
| Boehringer Ingelheim GmbH | 30 | 1 |
| Bristol-Myers Squibb Company | 31 | 1 |
| Covis Pharmaceuticals, Inc. | 32 | 1 |
| CSL Limited | 33 | 1 |
| Cumberland Pharmaceuticals, Inc. | 34 | 1 |
| Digna Biotech, S.L. | 35 | 1 |
| F. Hoffmann-La Roche Ltd. | 36 | 1 |
| Fibrocell Science, Inc. | 37 | 1 |
| GenKyoTex S.A. | 38 | 1 |
| Gilead Sciences, Inc. | 39 | 1 |
| GlaxoSmithKline Plc | 40 | 1 |
| iBio, Inc. | 41 | 1 |
| Inventiva | 42 | 1 |
| Kadmon Corporation, LLC | 43 | 1 |
| MedImmune, LLC | 44 | 1 |
| miRagen Therapeutics, Inc. | 45 | 1 |
| PDX Pharmaceuticals LLC | 46 | 1 |
| Peptinov SAS | 47 | 1 |
| ProMetic Life Sciences Inc. | 48 | 1 |
| Ribomic Inc. | 49 | 1 |
| Sanofi | 50 | 1 |
| Stemline Therapeutics, Inc. | 51 | 1 |
| Stratatech Corporation | 52 | 1 |
| Vida Therapeutics Inc. | 53 | 1 |
| VivaCell Biotechnology Espana S.L. | 54 | 1 |
| Systemic Sclerosis (Scleroderma) Therapeutics Assessment | 55 | 13 |
| Assessment by Monotherapy Products | 55 | 1 |
| Assessment by Target | 56 | 4 |
| Assessment by Mechanism of Action | 60 | 4 |
| Assessment by Route of Administration | 64 | 2 |
| Assessment by Molecule Type | 66 | 2 |
| Drug Profiles | 68 | 101 |
| abatacept Drug Profile | 68 | 5 |
| acALY-18 Drug Profile | 73 | 1 |
| acetylcysteine Drug Profile | 74 | 1 |
| ambrisentan Drug Profile | 75 | 2 |
| ANG-3070 Drug Profile | 77 | 1 |
| belimumab Drug Profile | 78 | 6 |
| BL-1110 Drug Profile | 84 | 1 |
| BOT-191 Drug Profile | 85 | 1 |
| C-1889 Drug Profile | 86 | 2 |
| C-82 Drug Profile | 88 | 1 |
| Cell Therapy for Dermatology and Immunology Drug Profile | 89 | 2 |
| CM-101 Drug Profile | 91 | 1 |
| disitertide Drug Profile | 92 | 2 |
| factor XIII (human) Drug Profile | 94 | 1 |
| FCX-013 Drug Profile | 95 | 1 |
| GKT-831 Drug Profile | 96 | 3 |
| GSK-2330811 Drug Profile | 99 | 1 |
| IBIOCFB-03 Drug Profile | 100 | 2 |
| ifetroban sodium Drug Profile | 102 | 2 |
| IVA-337 Drug Profile | 104 | 1 |
| JBT-101 Drug Profile | 105 | 5 |
| KD-025 Drug Profile | 110 | 4 |
| M-10 Drug Profile | 114 | 1 |
| MEDI-7734 Drug Profile | 115 | 1 |
| MGN-4220 Drug Profile | 116 | 1 |
| Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders Drug Profile | 117 | 1 |
| nintedanib Drug Profile | 118 | 10 |
| nitroglycerin Drug Profile | 128 | 2 |
| Oligonucleotide for Scleroderma Drug Profile | 130 | 1 |
| onabotulinumtoxin A Drug Profile | 131 | 5 |
| PAT-048 Drug Profile | 136 | 1 |
| PBI-4050 Drug Profile | 137 | 5 |
| PDX-002 Drug Profile | 142 | 1 |
| PPV-06 Drug Profile | 143 | 1 |
| RBM-006 Drug Profile | 144 | 1 |
| riociguat Drug Profile | 145 | 6 |
| RP-182 Drug Profile | 151 | 1 |
| SAR-100842 Drug Profile | 152 | 1 |
| SAR-317461 Drug Profile | 153 | 1 |
| Small Molecule to Inhibit NFkB for Immunology and Oncology Drug Profile | 154 | 1 |
| SRI-35241 Drug Profile | 155 | 1 |
| Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis Drug Profile | 156 | 1 |
| terguride Drug Profile | 157 | 1 |
| tocilizumab Drug Profile | 158 | 8 |
| VCE-0048 Drug Profile | 166 | 1 |
| VEDA-1209 Drug Profile | 167 | 1 |
| VTI-1000 Series Drug Profile | 168 | 1 |
| Systemic Sclerosis (Scleroderma) Dormant Projects | 169 | 3 |
| Systemic Sclerosis (Scleroderma) Discontinued Products | 172 | 1 |
| Systemic Sclerosis (Scleroderma) Product Development Milestones | 173 | 10 |
| Featured News &Press Releases | 173 | 1 |
| Jul 05, 2016: iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate | 173 | 1 |
| Jun 29, 2016: Fibrocell Announces Update on FCX-013 | 173 | 1 |
| Jun 16, 2016: Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis | 174 | 1 |
| Apr 27, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Vasculan For Systemic Sclerosis | 174 | 1 |
| Apr 25, 2016: Fibrocell Receives Orphan Drug Designation from the FDA for FCX-013 for the Treatment of Localized Scleroderma | 175 | 1 |
| Apr 12, 2016: Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis | 176 | 1 |
| Mar 17, 2016: Chugai receives Orphan Drug Designation for Tocilizumab in Systemic Scleroderma | 177 | 1 |
| Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications | 177 | 1 |
| Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress | 178 | 1 |
| Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge | 178 | 1 |
| Dec 08, 2015: New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis | 179 | 1 |
| Nov 12, 2015: miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-201 | 180 | 1 |
| Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis | 181 | 1 |
| Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum | 181 | 1 |
| Oct 07, 2015: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis | 182 | 1 |
| Appendix | 183 | 2 |
| Methodology | 183 | 1 |
| Coverage | 183 | 1 |
| Secondary Research | 183 | 1 |
| Primary Research | 183 | 1 |
| Expert Panel Validation | 183 | 1 |
| Contact Us | 183 | 1 |
| Disclaimer | 184 | 1 |